The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1-like receptors

F. Facchinetti, R. E. Nappi, G. Sances, L. Fioroni, G. Nappi, A. R. Genazzani

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective - A relationship between the serotoninergic and the opiatergic system in the pathogenesis of head pain is supported by several data. This study was carried out to Investigate the neuroendocrine effects of sumatriptan, a specific serotonin agonist used in the treatment of migraine, on hypothalamic-pituitary-adrenal axis (PHA) hormones. Design - Two consecutive studies were performed. In study A, eight subjects received a subcutaneous (s.c.) Injection of sumatriptan (6 mg). In study B, a further six subjects were randomized to receive either sumatriptan or placebo. Subjects - Healthy volunteers recruited within the staff (eight males and six females) were studied. Measurement - In study A, plasma cortisol and PRL were measured by direct RIA and β-endorphin after extraction and chromatography. Samples were collected from 60 minutes before to 120 minutes after the administration of the drug, at 15-minute intervals. According to the data of the first study, in study B, in addition to cortisol and β-endorphin, ACTH was also measured. Results - Significant increases in the mean β-endorphin and cortisol concentrations were found in every subject receiving sumatriptan, while no significant changes were observed in prolactin plasma levels. Study B confirmed the activation of the pituitary-adrenal axis, additionally demonstrating the release of ACTH, and indicated that placebo has no effects. Conclusion - Acute s.c. stimulation with sumatriptan activates the pituitary-adrenal axis.

Original languageEnglish
Pages (from-to)211-214
Number of pages4
JournalClinical Endocrinology
Volume40
Issue number2
Publication statusPublished - 1994

Fingerprint

Serotonin 5-HT1 Receptors
Sumatriptan
Endorphins
Ligands
Hydrocortisone
Adrenocorticotropic Hormone
Placebos
Serotonin Receptor Agonists
Subcutaneous Injections
Migraine Disorders
Prolactin
Headache
Chromatography
Healthy Volunteers
Hormones
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology

Cite this

The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1-like receptors. / Facchinetti, F.; Nappi, R. E.; Sances, G.; Fioroni, L.; Nappi, G.; Genazzani, A. R.

In: Clinical Endocrinology, Vol. 40, No. 2, 1994, p. 211-214.

Research output: Contribution to journalArticle

Facchinetti, F, Nappi, RE, Sances, G, Fioroni, L, Nappi, G & Genazzani, AR 1994, 'The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1-like receptors', Clinical Endocrinology, vol. 40, no. 2, pp. 211-214.
Facchinetti, F. ; Nappi, R. E. ; Sances, G. ; Fioroni, L. ; Nappi, G. ; Genazzani, A. R. / The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1-like receptors. In: Clinical Endocrinology. 1994 ; Vol. 40, No. 2. pp. 211-214.
@article{6967cde67b3c4a4cbd39e072d1ad5419,
title = "The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1-like receptors",
abstract = "Objective - A relationship between the serotoninergic and the opiatergic system in the pathogenesis of head pain is supported by several data. This study was carried out to Investigate the neuroendocrine effects of sumatriptan, a specific serotonin agonist used in the treatment of migraine, on hypothalamic-pituitary-adrenal axis (PHA) hormones. Design - Two consecutive studies were performed. In study A, eight subjects received a subcutaneous (s.c.) Injection of sumatriptan (6 mg). In study B, a further six subjects were randomized to receive either sumatriptan or placebo. Subjects - Healthy volunteers recruited within the staff (eight males and six females) were studied. Measurement - In study A, plasma cortisol and PRL were measured by direct RIA and β-endorphin after extraction and chromatography. Samples were collected from 60 minutes before to 120 minutes after the administration of the drug, at 15-minute intervals. According to the data of the first study, in study B, in addition to cortisol and β-endorphin, ACTH was also measured. Results - Significant increases in the mean β-endorphin and cortisol concentrations were found in every subject receiving sumatriptan, while no significant changes were observed in prolactin plasma levels. Study B confirmed the activation of the pituitary-adrenal axis, additionally demonstrating the release of ACTH, and indicated that placebo has no effects. Conclusion - Acute s.c. stimulation with sumatriptan activates the pituitary-adrenal axis.",
author = "F. Facchinetti and Nappi, {R. E.} and G. Sances and L. Fioroni and G. Nappi and Genazzani, {A. R.}",
year = "1994",
language = "English",
volume = "40",
pages = "211--214",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1-like receptors

AU - Facchinetti, F.

AU - Nappi, R. E.

AU - Sances, G.

AU - Fioroni, L.

AU - Nappi, G.

AU - Genazzani, A. R.

PY - 1994

Y1 - 1994

N2 - Objective - A relationship between the serotoninergic and the opiatergic system in the pathogenesis of head pain is supported by several data. This study was carried out to Investigate the neuroendocrine effects of sumatriptan, a specific serotonin agonist used in the treatment of migraine, on hypothalamic-pituitary-adrenal axis (PHA) hormones. Design - Two consecutive studies were performed. In study A, eight subjects received a subcutaneous (s.c.) Injection of sumatriptan (6 mg). In study B, a further six subjects were randomized to receive either sumatriptan or placebo. Subjects - Healthy volunteers recruited within the staff (eight males and six females) were studied. Measurement - In study A, plasma cortisol and PRL were measured by direct RIA and β-endorphin after extraction and chromatography. Samples were collected from 60 minutes before to 120 minutes after the administration of the drug, at 15-minute intervals. According to the data of the first study, in study B, in addition to cortisol and β-endorphin, ACTH was also measured. Results - Significant increases in the mean β-endorphin and cortisol concentrations were found in every subject receiving sumatriptan, while no significant changes were observed in prolactin plasma levels. Study B confirmed the activation of the pituitary-adrenal axis, additionally demonstrating the release of ACTH, and indicated that placebo has no effects. Conclusion - Acute s.c. stimulation with sumatriptan activates the pituitary-adrenal axis.

AB - Objective - A relationship between the serotoninergic and the opiatergic system in the pathogenesis of head pain is supported by several data. This study was carried out to Investigate the neuroendocrine effects of sumatriptan, a specific serotonin agonist used in the treatment of migraine, on hypothalamic-pituitary-adrenal axis (PHA) hormones. Design - Two consecutive studies were performed. In study A, eight subjects received a subcutaneous (s.c.) Injection of sumatriptan (6 mg). In study B, a further six subjects were randomized to receive either sumatriptan or placebo. Subjects - Healthy volunteers recruited within the staff (eight males and six females) were studied. Measurement - In study A, plasma cortisol and PRL were measured by direct RIA and β-endorphin after extraction and chromatography. Samples were collected from 60 minutes before to 120 minutes after the administration of the drug, at 15-minute intervals. According to the data of the first study, in study B, in addition to cortisol and β-endorphin, ACTH was also measured. Results - Significant increases in the mean β-endorphin and cortisol concentrations were found in every subject receiving sumatriptan, while no significant changes were observed in prolactin plasma levels. Study B confirmed the activation of the pituitary-adrenal axis, additionally demonstrating the release of ACTH, and indicated that placebo has no effects. Conclusion - Acute s.c. stimulation with sumatriptan activates the pituitary-adrenal axis.

UR - http://www.scopus.com/inward/record.url?scp=0028225175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028225175&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 211

EP - 214

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -